Limited Potentiation of Blood Pressure in Response to Oral Tyramine by the Anti-Parkinson Brain Selective Multifunctional Monoamine Oxidase-AB Inhibitor, M30

Abassi ZA, Binah O, Youdim MB (2004) Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol 143:371–378

Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB (2007a) Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer’s disease. J Neurochem 100:490–502

Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, Mandel S, Youdim MB (2007b) Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4:403–411

Ben-Shachar D, Eshel G, Finberg JP, Youdim MB (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56:1441–1444

Ben-Shachar D, Kahana N, Kampel V, Warshawsky A, Youdim MB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46:254–263

Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A (2004) Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J Med Chem 47:1767–1774

Blackwell B, Marley E (1966) Interactions of cheese and of its constituents with monoamine oxidase inhibitors. Br J Pharmacol Chemother 26:120–141

Blackwell B, Marley E, Price J, Taylor D (1967) Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 113:349–365

Da Prada M, Zurcher G, Wuthrich I, Haefely WE (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl 26:31–56

Finberg JP, Tenne M (1982) Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol 77:13–21

Finberg JP, Tenne M, Youdim MBH (1981) Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 73:65–74

Gal S, Zheng H, Fridkin M, Youdim MB (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95:79–88

Gal S, Fridkin M, Amit T, Zheng H, Youdim MB (2006) M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease. J Neural Transm Suppl 70:447–456

Gal S, Zheng H, Fridkin M, Youdim MB (2009) Restoration of nigrostriatal dopamine neurons in post-mptp treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res [Epub ahead of print]

Green AR, Mitchell BD, Tordoff AF, Youdim MBH (1977) Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol 60:343–349

Hall S, Rutledge JN, Schallert T (1992) MRI, brain iron and experimental Parkinson’s disease. J Neurol Sci 113:198–208

Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS (2004) Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J Neurosci 24:2045–2053

Kalir A, Sabbagh A, Youdim MBH (1981) Selective acetylenic ‘suicide’ and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 73:55–64

Keller R, Oke A, Mefford I, Adams R (1976) Liquid chromatographic analysis of catecholamines routine assay for regional brain mapping. Life Sci 19:995–1003

Lamensdorf I, Youdim MBH, Finberg JP (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67:1532–1539

Lin YL, Lin JK (1997) (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol 52:465–472

Lin M, Rippe RA, Niemela O, Brittenham G, Tsukamoto H (1997) Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am J Physiol 272:G1355–G1364

O’Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF (1983) The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 322:198–202

Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660:8–18

Paykel ES (1995) Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression. Acta Psychiatr Scand Suppl 386:22–27

Tipton KF, Youdim MB (1976) Assay of monoamine oxidase. In: Wolstenholeme GEW, Knight J (eds) Monoamine oxidase and its inhibition. Excerpta Medica, North Holland, pp 393–403

Tipton KF, Houslay MD, Mantle TJ (1976) The nature and locations of the multiple forms of monoamine oxidase. In: Monoamine oxidase and its inhibition. Ciba Foundation Symposium 39. Elsevier, Amsterdam, pp 5–31

Tipton KF, O’Sullivan J, Youdim MB (2004) Monoamine oxidase (MAO): functions in the central nervous system. In: Adelman G, Smith BH (eds) Encyclopedia of neuroscience, 3rd edn. Elsevier, Amsterdam

Weinstock M, Goren T, Youdim MBH (2000a) Development of a novel neuroprotective drug (TV3326) for the treatment of alzheimer’s disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev Res 50:216–222

Weinstock M, Bejar C, Wang RH, Poltyrev T, Gross A, Finberg J, Youdim MBH (2000b) TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer’s disease. J Neural Transm Suppl 60:S157–S169

Weinstock M, Gorodetsky E, Wang RH, Gross A, Weinreb O, Youdim MBH (2002) Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits(1). Neuropharmacology 43:999–1005

Wong KP (1976) The conjugation of tyramine with sulphate by liver and intestine of different animals. Biochem J 160:491–493

Youdim MB, Bakhle YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br J Pharmacol 147 Suppl 1:S287–S296

Youdim MB, Riederer PF (2004) A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson’s disease. Neurology 63:S32–S35

Youdim MB, Riederer PF (2007) Monoamine oxidase A and B inhibitors in Parkinson’s disease. Handb Clin Neurol 84:93–120

Youdim MB, Weinstock M (2004) Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology 25:243–250

Youdim MBH, Finberg JPM, Tipton KF (1988) Monoamine oxidase. In: Trendelenburg U, Weiner N (eds) Catecholamine II. Handbook of experimental pharmacology. Springer-Verlag, Berlin, pp 127–199

Youdim MBH, Gross A, Finberg JPM (2001) Rasagiline [N-Propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132:500–506

Youdim MB, Edmondson D, Tipton KF (2006a) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295–309

Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M (2006b) Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotox Res 10:181–192

Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB (2005a) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95:68–78

Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MBH, Fridkin M (2005b) Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Bioorganic Med Chem 13:773–783

Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim MB, Le W (2007) Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21:3835–3844

Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, Le W (2008) Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 105:1970–1978